Skip To Main Content
Ying-Jie Cui on Muck Rack

Ying-Jie Cui

As seen in: ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying-Jie

Contact Ying-Jie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy

|
By Abdellah Allali-Hassani, Masoud Vedadi, Ying-Jie Cui, S. Makin
| ScienceDirect Verified
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancer pathological types worldwide, and it has special biological behavior and clinicopathological characteristics [1]. Because the loss of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression is negative, endocrine therapy is basically ineffective for TNBC, and targeted therapy is not sensitive, so TNBC is also known as the terminal disease of breast cancer [2,3].
Open in Who Shared Issue with article?

Development of novel quinoline-NO donor hybrids inducing human breast cancer cells apoptosis via inhibition of topoisomerase I

|
By Jayendra Patel, Y. Pommier, Matej Zore, Ying-Jie Cui
| ScienceDirect Verified
Introduction Previous research has reported that quinoline and its derivatives could inhibit the activity of topoisomerase I (Topo I), which was considered as important target for the prevention of rapid proliferation of cancer cells1, 2. Several quinoline derived Topo I inhibitors, such as camptothecin and its derivatives (1, Neratinib Maleate and Bosutinib, Figure 1), have been widely used in the clinic for decades as anti-cancer drugs.
Open in Who Shared Issue with article?
See all 2 articles